PCSK9 Cholesterol Drugs And FDA’s Missing Mandatory Study Authority
This article was originally published in RPM Report
FDA has some work to do to interpret the Endocrinologic & Metabolic Drugs Advisory Committee’s advice about whether and when LDL-lowering can be treated as a fully valid surrogate endpoint to support approval. The issue would probably be a lot simpler for FDA—and the sponsors of a new class of highly effective LDL-lowering therapies—if FDA had authority to mandate trials for efficacy.
Register for our free email digests: